When will PharmaTher report earnings and why does it matter for PHRM.CN stock?

PharmaTher announces results on 23 Jan 2026. The report matters because management comments and trial updates can move the stock sharply, given its small market cap and event-driven valuation.

What is Meyka AI's forecast for PHRM.CN stock and how should investors use it?

Meyka AI's forecast model projects a one-year level near C$0.28, an implied upside of +208.94% from C$0.09. Forecasts are model-based projections and not guarantees.

What are the main risks that could hurt PharmaTher shares after earnings?

Primary risks include negative or delayed clinical readouts, funding shortfalls that cause dilution, and weak commercialization or partner updates. Low liquidity can amplify downside moves.

How does the market currently value PharmaTher compared with peers?

PHRM.CN has a high PB ratio near 10.43 despite limited revenue, reflecting speculative pricing. Sector peers typically show stronger revenue and lower PB, highlighting elevated valuation risk.

CA Stocks

PHRM.CN PharmaTher Holdings (CNQ) at C$0.09 ahead of Jan 23 earnings: catalysts to watch 20 Jan 2026

ByHuzaifa Zahoor January 20, 2026January 20, 2026

Shares of PharmaTher Holdings Ltd. (PHRM.CN) trade at C$0.09 as the company prepares to report results on 23 Jan 2026. The PHRM.CN stock sits near its daily low of C$0.085 and shows thin liquidity with volume 98,577 shares. We preview the earnings drivers, clinical milestones, and short-term price scenarios that could move the stock during market hours in Canada.